Navigation Links
First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
Date:3/11/2013

MONMOUTH JUNCTION, N.J., March 11, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01.

Under the collaboration, POC required the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. Assuming continued clinical success, Tris expects to file a New Drug Application with the U.S. Food & Drug Administration for CCP-01 in mid-2014.

"We're very pleased to have achieved proof-of-concept for CCP-01," said Ketan Mehta , President and CEO of Tris Pharma. "Our propriety OralXR+™ technology is ideally suited to bring long-lasting relief to U.S. cough and cold sufferers, which our research has identified as a significant unmet need."

Ian Garland , CEO of Vernalis, commented, "We are delighted with this early success in our collaboration with Tris and look forward to a productive 2013 when we anticipate further significant progress for our cough/cold pipeline."

Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+ based extended-release liquid equivalents to existing immediate release prescription cough/cold treatments. The companies have not disclosed the financial terms of their collaboration.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.

 


'/>"/>
SOURCE Tris Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
(Date:5/24/2016)... Een app die artsen over ... patiënten kunnen behandelen, hun kennis kunnen delen en van ... nieuwe en revolutionaire MDLinking App, ontwikkeld door een internationale ... Hans Flu en oncologisch chirurg dr. Gijs van ... wordt op dinsdag 24 mei officieel gepresenteerd op het ...
(Date:5/23/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the ... The hands-on learning experience is a 12-week summer program, ... Fellowship and Internship programs bring participants ... interns are provided optional housing free of charge through ... the Riverfront Residence Hall to foster communication and collaboration ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... and managed services today announced a strategic partnership with Five9 (Nasdaq: FIVN), ... , Altura, one of Avaya’s largest Platinum Business Partners, is a leading ...
(Date:5/24/2016)... ... 2016 , ... Local engineering firm, Timmons Group, announced the ... in Woodbridge, VA. The project includes a brand new operating room addition ... new 2 story building houses the Central Sterile department, Sterile prep area and ...
(Date:5/24/2016)... ... 2016 , ... New Brunswick, New Jersey: This year marks Children’s Specialized Hospital ... To commemorate the anniversary, the hospital has themed the milestone “Hats Off” and kicked ... Hospital Foundation on Saturday, May 21, at Johnson Park in Piscataway, New Jersey. ...
(Date:5/24/2016)... Freeport, Grand Bahama (PRWEB) , ... May 24, 2016 , ... ... rapid pace. Such breakthroughs in adult stem cell therapy technology, protocols and patient results ... for this emerging field to become a more accessible standard of care for patients ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has ... and expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the ... event photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, ...
Breaking Medicine News(10 mins):